There are multiple reasons to enhance developability for an existing candidate.
Our AI-powered workflow can enhance antibody developability while keeping other crucial properties intact.
Case 1-3Enhancing antibody developability to acceptable levels

We utilized our AI-driven workflow to enhance 3 antibodies with known developability risks. All 3 resulted in variants with substantial improvement. Fewer than 15 variants of each were expressed and tested to achieve the above results.

Case 1: Aggregation reduction of Bevacizumab (Formulated in 50 mM PB buffer, incubated at 52 °C)

Case 2: Improvement of both Tm & Tagg for Eldelumab

Case 3: Viscosity reduction for a highly-viscous antibody

Case 4Enhancing recombinant cytokine developability for BIC profile